The National Lung Matrix Trial of personalized therapy in lung cancer

Gary Middleton (), Peter Fletcher, Sanjay Popat, Joshua Savage, Yvonne Summers, Alastair Greystoke, David Gilligan, Judith Cave, Noelle O’Rourke, Alison Brewster, Elizabeth Toy, James Spicer, Pooja Jain, Adam Dangoor, Melanie Mackean, Martin Forster, Amanda Farley, Dee Wherton, Manita Mehmi, Rowena Sharpe, Tara C. Mills, Maria Antonietta Cerone, Timothy A. Yap, Thomas B. K. Watkins, Emilia Lim, Charles Swanton and Lucinda Billingham
Additional contact information
Gary Middleton: University of Birmingham
Peter Fletcher: University of Birmingham
Sanjay Popat: The Royal Marsden Hospital
Joshua Savage: University of Birmingham
Yvonne Summers: The Christie
Alastair Greystoke: Newcastle University
David Gilligan: Addenbrooke’s Hospital
Judith Cave: Southampton University Hospitals NHS Trust
Noelle O’Rourke: Beatson West of Scotland Cancer Centre
Alison Brewster: Velindre Cancer Centre
Elizabeth Toy: Royal Devon and Exeter Foundation NHS Trust
James Spicer: Guy’s Hospital
Pooja Jain: St James’s University Hospital
Adam Dangoor: Bristol Haematology and Oncology Centre
Melanie Mackean: Western General Hospital
Martin Forster: University College Hospital
Amanda Farley: University of Birmingham
Dee Wherton: University of Birmingham
Manita Mehmi: University of Birmingham
Rowena Sharpe: University of Birmingham
Tara C. Mills: Cancer Research UK
Maria Antonietta Cerone: Cancer Research UK
Timothy A. Yap: The University of Texas, MD Anderson Cancer Center
Thomas B. K. Watkins: The Francis Crick Institute
Emilia Lim: The Francis Crick Institute
Charles Swanton: The Francis Crick Institute
Lucinda Billingham: University of Birmingham

Nature, 2020, vol. 583, issue 7818, 807-812

Abstract: Abstract The majority of targeted therapies for non-small-cell lung cancer (NSCLC) are directed against oncogenic drivers that are more prevalent in patients with light exposure to tobacco smoke1–3. As this group represents around 20% of all patients with lung cancer, the discovery of stratified medicine options for tobacco-associated NSCLC is a high priority. Umbrella trials seek to streamline the investigation of genotype-based treatments by screening tumours for multiple genomic alterations and triaging patients to one of several genotype-matched therapeutic agents. Here we report the current outcomes of 19 drug–biomarker cohorts from the ongoing National Lung Matrix Trial, the largest umbrella trial in NSCLC. We use next-generation sequencing to match patients to appropriate targeted therapies on the basis of their tumour genotype. The Bayesian trial design enables outcome data from open cohorts that are still recruiting to be reported alongside data from closed cohorts. Of the 5,467 patients that were screened, 2,007 were molecularly eligible for entry into the trial, and 302 entered the trial to receive genotype-matched therapy—including 14 that re-registered to the trial for a sequential trial drug. Despite pre-clinical data supporting the drug–biomarker combinations, current evidence shows that a limited number of combinations demonstrate clinically relevant benefits, which remain concentrated in patients with lung cancers that are associated with minimal exposure to tobacco smoke.

Date: 2020
References: Add references at CitEc
Citations: View citations in EconPapers (2)

Downloads: (external link)
https://www.nature.com/articles/s41586-020-2481-8 Abstract (text/html)
Access to the full text of the articles in this series is restricted.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:nature:v:583:y:2020:i:7818:d:10.1038_s41586-020-2481-8

Ordering information: This journal article can be ordered from
https://www.nature.com/

DOI: 10.1038/s41586-020-2481-8

Access Statistics for this article

Nature is currently edited by Magdalena Skipper

More articles in Nature from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().